ImmunityBio (IBRX) announced completion of enrollment in its Phase 2 clinical trial evaluating Anktiva plus Bacillus Calmette-Guerin versus BCG alone in patients with BCG-naive non-muscle invasive bladder cancer carcinoma in situ, with or without papillary tumors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IBRX: